|
1
|
Nakajima M, Rauramaa T, Mäkinen PM, Hiltunen M, Herukka SK, Kokki M, Musialowicz T, Jyrkkänen HK, Danner N, Junkkari A, Koivisto AM, Jääskeläinen JE, Miyajima M, Ogino I, Furuta A, Akiba C, Kawamura K, Kamohara C, Sugano H, Tange Y, Karagiozov K, Leinonen V, Arai H. Protein tyrosine phosphatase receptor type Q in cerebrospinal fluid reflects ependymal cell dysfunction and is a potential biomarker for adult chronic hydrocephalus. Eur J Neurol 2020; 28:389-400. [PMID: 33035386 PMCID: PMC7821334 DOI: 10.1111/ene.14575] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2020] [Accepted: 09/30/2020] [Indexed: 01/02/2023]
Abstract
BACKGROUND AND PURPOSE Protein tyrosine phosphatase receptor type Q (PTPRQ) was extracted from the cerebrospinal fluid (CSF) of patients with probable idiopathic normal-pressure hydrocephalus (iNPH) by proteome analysis. We aimed to assess the feasibility of using CSF PTPRQ concentrations for the additional diagnostic criterion of iNPH in Japanese and Finnish populations. METHODS We compared PTPRQ concentrations among patients with probable iNPH and neurologically healthy individuals (normal control [NC] group), patients with normal-pressure hydrocephalus (NPH) of acquired and congenital/developmental aetiologies, patients with Alzheimer's disease and patients with Parkinson's disease in a Japanese analysis cohort. A corresponding iNPH group and NC group in a Finnish cohort was used for validation. Patients in the Finnish cohort who underwent biopsy were classified into two groups based on amyloid and/or tau deposition. We measured PTPRQ expression levels in autopsied brain specimens of iNPH patients and the NC group. RESULTS Cerebrospinal fluid PTPRQ concentrations in the patients with NPH of idiopathic, acquired and congenital/developmental aetiologies were significantly higher than those in the NC group and those with Parkinson's disease, but iNPH showed no significant differences when compared with those in the Alzheimer's disease group. For the patients with iNPH, the area under the receiver-operating characteristic curve was 0.860 in the Japanese iNPH and 0.849 in the Finnish iNPH cohorts. Immunostaining and in situ hybridization revealed PTPRQ expression in the ependymal cells and choroid plexus. It is highly possible that the elevated PTPRQ levels in the CSF are related to ependymal dysfunction from ventricular expansion. CONCLUSIONS Cerebrospinal fluid PTPRQ levels indicated the validity of this assay for auxiliary diagnosis of adult chronic hydrocephalus.
Collapse
Affiliation(s)
- M Nakajima
- Department of Neurosurgery, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - T Rauramaa
- Institute of Clinical Medicine－Pathology, University of Eastern, Finland.,Department of Pathology, Kuopio University Hospital, Kuopio, Finland
| | - P M Mäkinen
- Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland
| | - M Hiltunen
- Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland
| | - S-K Herukka
- Institute of Clinical Medicine - Neurology, University of Eastern Finland, Kuopio, Finland.,Neurocentre, Neurology, Kuopio University Hospital, Kuopio, Finland
| | - M Kokki
- Department of Anaesthesiology and Intensive Care, Kuopio University Hospital, Kuopio, Finland
| | - T Musialowicz
- Department of Anaesthesiology and Intensive Care, Kuopio University Hospital, Kuopio, Finland
| | - H-K Jyrkkänen
- Institute of Clinical Medicine－Neurosurgery, University of Eastern, Finland.,Neurocentre, Neurosurgery, Kuopio University Hospital, Kuopio, Finland
| | - N Danner
- Institute of Clinical Medicine－Neurosurgery, University of Eastern, Finland.,Neurocentre, Neurosurgery, Kuopio University Hospital, Kuopio, Finland
| | - A Junkkari
- Institute of Clinical Medicine－Neurosurgery, University of Eastern, Finland.,Neurocentre, Neurosurgery, Kuopio University Hospital, Kuopio, Finland
| | - A M Koivisto
- Institute of Clinical Medicine - Neurology, University of Eastern Finland, Kuopio, Finland.,Neurocentre, Neurology, Kuopio University Hospital, Kuopio, Finland
| | - J E Jääskeläinen
- Institute of Clinical Medicine－Neurosurgery, University of Eastern, Finland.,Neurocentre, Neurosurgery, Kuopio University Hospital, Kuopio, Finland
| | - M Miyajima
- Department of Neurosurgery, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - I Ogino
- Department of Neurosurgery, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - A Furuta
- Department of Psychiatry and Behavioural Science, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - C Akiba
- Department of Neurosurgery, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - K Kawamura
- Department of Neurosurgery, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - C Kamohara
- Department of Neurosurgery, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - H Sugano
- Department of Neurosurgery, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - Y Tange
- Department of Neurosurgery, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - K Karagiozov
- Department of Neurosurgery, Juntendo University Faculty of Medicine, Tokyo, Japan
| | - V Leinonen
- Institute of Clinical Medicine－Neurosurgery, University of Eastern, Finland.,Neurocentre, Neurosurgery, Kuopio University Hospital, Kuopio, Finland.,Unit of Clinical Neuroscience, Neurosurgery, University of Oulu and Medical Research Centre, Oulu University Hospital, Oulu, Finland
| | - H Arai
- Department of Neurosurgery, Juntendo University Faculty of Medicine, Tokyo, Japan
| |
Collapse
|